- Home
- DOCS vs APGE Comparison
DOCS vs APGE Comparison
Compare DOCS & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOCS | APGE |
|---|---|---|
| Founded | 2010 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.7B |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | DOCS | APGE |
|---|---|---|
| Price | $22.29 | $134.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 13 |
| Target Price | $45.50 | ★ $109.67 |
| AVG Volume (30 Days) | 3.1M | ★ 5.4M |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.98 | N/A |
| Revenue | ★ $644,863,000.00 | N/A |
| Revenue This Year | $15.08 | N/A |
| Revenue Next Year | $8.83 | N/A |
| P/E Ratio | $22.26 | ★ N/A |
| Revenue Growth | ★ 13.05 | N/A |
| 52 Week Low | $17.15 | $34.34 |
| 52 Week High | $76.51 | $134.21 |
Technical Indicators
Market Signals| Indicator | DOCS | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 55.64 | 81.67 |
| Support Level | $19.92 | $80.52 |
| Resistance Level | $23.11 | N/A |
| Average True Range (ATR) | 0.94 | 0.42 |
| MACD | 0.13 | -1.00 |
| Stochastic Oscillator | 65.05 | 96.20 |
Price Performance
Historical ComparisonAbout DOCS Doximity Inc.
Doximity Inc is a digital platform for U.S. medical professionals. The cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers and on-call schedules.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.